https://scholars.lib.ntu.edu.tw/handle/123456789/494555
標題: | Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients | 作者: | Chow L.W.C. Biganzoli L. Leo A.D. Kuroi K. Han H.S. Patel J. CHIUN-SHENG HUANG YEN-SHEN LU Zhu L. Chow C.Y.C. Loo W.T.Y. Gl?ck S. Toi M. |
公開日期: | 2017 | 出版社: | Blackwell Publishing Ltd | 卷: | 13 | 期: | 6 | 起(迄)頁: | 372-378 | 來源出版物: | Asia-Pacific Journal of Clinical Oncology | 摘要: | Aim: For early-stage breast cancer, four cycles of docetaxel and cyclophosphamide (TC) was proven superior to doxorubicin plus cyclophosphamide in the US Oncology 9375 trial. Given primary prophylactic antibiotics, 5% febrile neutropenia was recorded in a population comprising 75.5% Caucasians. Smaller trials and retrospective studies reviewing TC use in Asian patients did not produce similar incidence rates. This study aims to discover the variable hematological toxicities with TC use in Caucasian and Asian patients. Methods: Breast cancer data was retrospectively reviewed for patients receiving adjuvant docetaxel 60–75 mg/m2 plus cyclophosphamide 600 mg/m2 from six countries (China, Hong Kong, Japan, Taiwan, Italy, and United States). Similar number of patients with relatively balanced baseline characteristics were chosen for analysis of hematological and nonhematological toxicities and survival data. Results: From March 2004 to July 2013, data of 227 patients (127 Asians and 100 Caucasian) patients were analyzed for treatment-related toxicities. During the four cycles of TC, Asians had a significantly higher rate of grade ?2 neutropenia than Caucasians (45.7% vs 6.0%; P <0.001) and significantly more grade ?3 neutropenia events were documented (respectively 30.7% vs 4.0%, P <0.001). The prophylactic use of G-CSF was similar; 26.0% in Asians and 28.0% in Caucasian (P = 0.764). There were no differences in nonhematological toxicities. No significant difference in disease-free survival was observed between Asians and Caucasians (log-rank P = 0.910). Conclusions: Ethnic differences in toxicity profile exist between Asian and Caucasian patients given adjuvant TC. Over 30% Asians but less than 5% Caucasians experienced grade ?3 neutropenia. ? 2017 John Wiley & Sons Australia, Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017248566&doi=10.1111%2fajco.12682&partnerID=40&md5=e28272eaed4584999edeed291dea944f https://scholars.lib.ntu.edu.tw/handle/123456789/494555 |
ISSN: | 1743-7555 | DOI: | 10.1111/ajco.12682 | SDG/關鍵字: | cyclophosphamide; docetaxel; docetaxel; taxoid; adjuvant therapy; adult; adverse outcome; anemia; Article; Asian; breast cancer; cancer adjuvant therapy; cancer staging; cancer survival; Caucasian; China; cohort analysis; diarrhea; disease free survival; drug effect; drug efficacy; ethnic difference; febrile neutropenia; female; hand foot syndrome; Hong Kong; human; Italy; Japan; liver toxicity; major clinical study; middle aged; mucosa inflammation; multiple cycle treatment; nausea; neutropenia; priority journal; retrospective study; Taiwan; thrombocytopenia; treatment outcome; trend study; United States; vomiting; Asian continental ancestry group; breast tumor; Caucasian; pathology; Asian Continental Ancestry Group; Breast Neoplasms; European Continental Ancestry Group; Female; Humans; Middle Aged; Retrospective Studies; Taxoids |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。